Kenneth Aldape

Oct 8, 2024 | nature.com | Jeffrey A. Zuccato |Yasin Mamatjan |Ammara Muazzam |Craig Simpson |Ming S. Tsao |Kenneth Aldape | +3 more

AbstractBrain metastases (BMs) are the most common and among the deadliest brain tumors. Currently, there are no reliable predictors of BM development from primary cancer, which limits early intervention. Lung adenocarcinoma (LUAD) is the most common BM source and here we obtained 402 tumor and plasma samples from a large cohort of patients with LUAD with or without BM (n = 346).

Jul 3, 2024 | nature.com | Danh-Tai Hoang |Eldad D. Shulman |Doreen S. Ben-Zvi |Sanju Sinha |Neelam Sinha |Christopher Dampier | +12 more

AbstractAdvances in artificial intelligence have paved the way for leveraging hematoxylin and eosin-stained tumor slides for precision oncology. We present ENLIGHT–DeepPT, an indirect two-step approach consisting of (1) DeepPT, a deep-learning framework that predicts genome-wide tumor mRNA expression from slides, and (2) ENLIGHT, which predicts response to targeted and immune therapies from the inferred expression values.

Jun 28, 2024 | digitalcommons.library.tmc.edu | Andrew B. Lassman |Stephanie Pugh |Kenneth Aldape |Hui K. Gan

BACKGROUND: Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp).

May 10, 2023 | nature.com | Yasin Mamatjan |Olivia Singh |Farshad Nassiri |Trevor J. Pugh |Gary D. Bader |Kenneth Aldape | +4 more

AbstractMalignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma, and a lethal neurofibromatosis type 1-related malignancy, with little progress made on treatment strategies. Here, we apply a multiplatform integrated molecular analysis on 108 tumors spanning the spectrum of peripheral nerve sheath tumors to identify candidate drivers of MPNST that can serve as therapeutic targets.